Analytical Data
-
Gene name
CDC123
- Application
-
Alternative Names
CDC123；C10orf7；D123；Translation initiation factor eIF2 assembly Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75794
-
Expression Region
1-336aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMKKEHVL HCQFSAWYPF FRGVTIKSVI LPLPQNVKDY LLDDGTLVVS GRDDPPTHSQ PDSDDEAEEI QWSDDENTAT LTAPEFPEFA TKVQEAINSL GGSVFPKLNW SAPRDAYWIA MNSSLKCKTL SDIFLLFKSS DFITRDFTQP FIHCTDDSPD PCIEYELVLR KWCELIPGAE FRCFVKENKL IGISQRDYTQ YYDHISKQKE EIRRCIQDFF KKHIQYKFLD EDFVFDIYRD SRGKVWLIDF NPFGEVTDSL LFTWEELISE NNLNGDFSEV DAQEQDSPAF RCTNSEVTVQ PSPYLSYRLP KDFVDLSTGE DAHKLIDFLK LKRNQQEDD
-
Molecular Weight
42 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDC123 is a protein involved in various cellular processes, particularly in cell cycle regulation and mitosis. Research into CDC123 has garnered attention due to its role in tumorigenesis and cellular proliferation. The protein interacts with several key regulators of the cell cycle, which makes it a potential target for cancer therapy. Abnormal expression or mutations in CDC123 have been implicated in various malignancies, further highlighting its importance in cancer biology. Recent studies have focused on characterizing the functional domains of CDC123, understanding its interaction network, and elucidating its role in oncogenic pathways. Additionally, the development of recombinant CDC123 protein has facilitated investigations into its structural properties and biological functions. By generating and studying this protein, researchers aim to uncover the molecular mechanisms through which CDC123 contributes to cell cycle dysregulation in cancer and to identify potential therapeutic strategies that could disrupt these processes. Through ongoing research, CDC123 may represent a promising avenue for the development of novel cancer treatments, providing insights into targeted therapies that could improve patient outcomes.
